ObjectiveTo analyze the effects of neoactivin on the myocardial microcirculation, cardiac function, cardiac injury markers and cardiac adverse events in patients with acute myocardial infarction complicated with heart failure after percutaneous coronary intervention(PCI).
MethodsA total of 120 patients with acute myocardial infarction complicated with heart failure from 2020 to 2021 were selected as the research objects, and randomly divided into the observation group and control group(60 cases in each group).All patients were treated with PCI surgery combined with intensive medical drug therapy.The observation group was additionally treated with neoactivin, while the control group was not treated with neoactivin.The therapeutic effects, cardiac function, myocardial microcirculation, myocardial injury markers and adverse events were compared between two groups.
ResultsThe therapeutic effects in observation group was significantly better than that in control group(P < 0.05).The left ventricular ejection fraction and left atrial diameter in observation group were significantly higher than those in control group, and the left ventricular end-diastolic volume and left ventricular diameter in observation group were significantly lower than those in control group(P < 0.01).The thrombolysis blood flow grading and frame count in observation group were lower than those in control group(P < 0.01).The level of cardiac troponin Ⅰ in observation group was lower than that in control group(P < 0.01).The incidence rates of adverse events of myocardial infarction, ventricular tachycardia and atrial fibrillation in observation group were lower than those in control group(P < 0.01).
ConclusionsThe treatment of acute myocardial infarction complicated with heart failure with neoactivin can significantly improve the myocardial microcirculation, cardiac function and cardiac injury markers, and reduce the incidence rates of adverse cardiac events.
DownLoad: